SEQ_NO	1	Date of announcement	2026/06/30	Time of announcement	17:40:44
Subject	Publication of the U.S. Phase I Clinical Trial of OBP-301 for Esophageal Cancer				
Date of events	2026/06/30	To which item it meets	paragraph 53		

Statement

1.Date of occurrence of the event:2026/06/30
2.Company name:Medigen Biotechnology Corp.
3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:
Medigen Biotechnology Corp. and the Japanese publicly traded company Oncolys BioPharma(“Oncolys”, TSE stock code 4588), are jointly developing the oncolytic virus new drug OBP-301 (Telomelysin). Oncolys announced today (June 30, 2026) that the U.S. Phase I clinical trial, NRG-GI007 (the“Study”), has published in the International Journal of Radiation Oncology・Biology・ Physics. The trial, conducted by NRG Oncology, evaluated OBP-301 in combination with chemoradiotherapy for patients with esophageal cancer. The publication is entitled ”NRG-GI007: Phase I Study of OBP-301, an Oncolytic Virus, and Definitive Chemoradiation in Locally Advanced Esophageal Cancer.”
The key findings of the Study are summarized as follows:
1.A total of 15 patients with esophageal cancer were enrolled in the Study. Fourteen patients completed OBP-301 administration according to the protocol of the clinical trial, while all 15 patients were included in the safety analysis. Of the 15 enrolled patients, 13 were included in the efficacy analysis after excluding two patients who died before treatment response could be evaluated.
2.No dose-limiting toxicities (DLTs) were observed during the study. Among the Grade 3 or Grade 4 serious adverse events considered related to the study treatment, the most common were neutropenia(40%) and lymphopenia(33%).
3.Among the 13 patients included in the efficacy analysis, the clinical complete response (clinical CR) rate was 100%. When all 15 enrolled patients were included, the clinical CR rate was 87%. After one year, 9 of the 15 enrolled patients (60%) were alive, and 8 patients(53%) remained progression-free.
As described above, OBP-301 in combination with chemoradiotherapy demonstrated an acceptable safety profile in patients with esophageal cancer, and all patients included in the efficacy analysis achieved a clinical CR. The future development strategy for OBP-301 will be determined following further evaluation and discussion of the study results.
6.Countermeasures:none
7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):
(1) Our company and Oncolys in Japan jointly share the development costs of OBP-301 and will share the future commercial benefits.
(2) Link to the announcement by Oncolys,Japan:
https://ssl4.eir-parts.net/doc/4588/tdnet/2845211/00.pdf